Literature DB >> 16091062

Trends in the prevalence of peptic ulcer disease and Helicobacter pylori infection in family physician-referred uninvestigated dyspeptic patients in Hong Kong.

B Xia1, H H X Xia, C W Ma, K W Wong, F M Y Fung, C K Hui, C K Chan, A O O Chan, K C Lai, M F Yuen, B C Y Wong.   

Abstract

BACKGROUND: Peptic ulcer disease is mainly caused by Helicobacter pylori infection and the use of non-steroidal anti-inflammatory drugs. AIM: To investigate the trends in the prevalence of peptic ulcer disease, H. pylori infection and non-steroidal anti-inflammatory drug use in uninvestigated dyspeptic patients over recent years in Hong Kong.
METHODS: Data from consecutive patients with uninvestigated dyspeptic symptoms referred by family physicians for open access upper endoscopy during 1997 and 2003 were analysed in relation to peptic ulcer disease, H. pylori infection and non-steroidal anti-inflammatory drug use.
RESULTS: Among 2700 patients included, 405 (15%) had peptic ulcer disease and 14 (0.5%) had gastric cancer. There was a reduced trend from 1997 to 2003 in the prevalence of peptic ulcer disease (17, 20, 14, 16, 13, 14 and 14%, respectively, chi2 = 5.80, P = 0.016) (mainly because of decrease in duodenal ulcers), H. pylori infection (44, 50, 49, 44, 40, 40, 36 and 43%, respectively, chi2 = 13.55, P < 0.001) and non-steroidal anti-inflammatory drug use (13, 5, 5, 6, 3, 4, 4 and 5% respectively, chi2 = 13.61, P < 0.001). The prevalence of peptic ulcer disease, H. pylori infection and non-steroidal anti-inflammatory drug use between 2001 and 2003 were significantly lower than that between 1997 and 2000 (17% vs. 13%, OR = 0.78, 95% CI: 0.63-0.96, P = 0.020 for peptic ulcer disease; 47% vs. 39%, OR =0.72, 95% CI: 0.60-0.86, P < 0.001 for H. pylori infection; and 6% vs. 4%, OR = 0.56, 95% CI: 0.39-0.82, P = 0.002 for non-steroidal anti-inflammatory drug use). H. pylori infection was associated with both duodenal ulcer (OR = 15.87, 95% CI: 10.60-23.76, P < 0.001) and gastric ulcer (OR = 3.12, 95% CI: 2.15-4.53, P < 0.001) whereas non-steroidal anti-inflammatory drug use was only associated with gastric ulcer (OR = 2.97, 95% CI: 1.70-5.20, P < 0.001).
CONCLUSIONS: The prevalence of peptic ulcer disease, mainly duodenal ulcers, was reduced in association with a decreasing trend in the prevalence of H. pylori infection and non-steroidal anti-inflammatory drug use from 1997 to 2003.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16091062     DOI: 10.1111/j.1365-2036.2005.02554.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  23 in total

1.  Prevalence and risk factors of asymptomatic peptic ulcer disease in Taiwan.

Authors:  Fu-Wei Wang; Ming-Shium Tu; Guang-Yuan Mar; Hung-Yi Chuang; Hsien-Chung Yu; Lung-Chih Cheng; Ping-I Hsu
Journal:  World J Gastroenterol       Date:  2011-03-07       Impact factor: 5.742

2.  Different peptic ulcer bleeding risk in chronic kidney disease and end-stage renal disease patients receiving different dialysis.

Authors:  Kuang-Wei Huang; Hsin-Bang Leu; Jiing-Chyuan Luo; Wan-Leong Chan; Ming-Chih Hou; Han-Chieh Lin; Fa-Yauh Lee; Yi-Chun Kuan
Journal:  Dig Dis Sci       Date:  2013-12-08       Impact factor: 3.199

3.  Time trends in epidemiology of peptic ulcer disease in India over two decades.

Authors:  Amit Kumar Dutta; Ashok Chacko; Avinash Balekuduru; Manoj Kumar Sahu; Sajith Kattiparambil Gangadharan
Journal:  Indian J Gastroenterol       Date:  2012-07-06

Review 4.  Helicobacter pylori-negative, non-steroidal anti-inflammatory drug: negative idiopathic ulcers in Asia.

Authors:  Katsunori Iijima; Takeshi Kanno; Tomoyuki Koike; Tooru Shimosegawa
Journal:  World J Gastroenterol       Date:  2014-01-21       Impact factor: 5.742

5.  Significant decrease in prevalence of Helicobacter pylori in the Czech Republic.

Authors:  Jan Bureš; Marcela Kopáčová; Ilona Koupil; Bohumil Seifert; Miluška Skodová Fendrichová; Jana Spirková; Viktor Voříšek; Stanislav Rejchrt; Tomáš Douda; Norbert Král; Ilja Tachecí
Journal:  World J Gastroenterol       Date:  2012-08-28       Impact factor: 5.742

6.  Efficacy of Zinc Sulfate in Peptic Ulcer Disease: A Randomized Double-Blind Clinical Trial Study.

Authors:  Kambiz Yazdanpanah; Baran Parhizkar; Farshad Sheikhesmaeili; Mohammad Roshani; Morteza Nayebi; Fardin Gharibi
Journal:  J Clin Diagn Res       Date:  2016-08-01

7.  Incidence of duodenal ulcers and gastric ulcers in a Western population: back to where it started.

Authors:  Marcel J M Groenen; Ernst J Kuipers; Bettina E Hansen; Rob J Th Ouwendijk
Journal:  Can J Gastroenterol       Date:  2009-09       Impact factor: 3.522

Review 8.  Therapeutic management of recurrent peptic ulcer disease.

Authors:  Raymond S Tang; Francis K L Chan
Journal:  Drugs       Date:  2012-08-20       Impact factor: 9.546

9.  Inverse time trends of peptic ulcer and reflux esophagitis show significant association with reduced prevalence of Helicobacter pylori infection.

Authors:  Nobutake Yamamichi; Yutaka Yamaji; Takeshi Shimamoto; Yu Takahashi; Kenichiro Majima; Ryoichi Wada; Tohru Mitsushima; Kazuhiko Koike
Journal:  Ann Med       Date:  2020-06-22       Impact factor: 4.709

Review 10.  Role of childhood infection in the sequelae of H. pylori disease.

Authors:  Paul R Harris; Lesley E Smythies; Phillip D Smith; Guillermo I Perez-Perez
Journal:  Gut Microbes       Date:  2013-11-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.